SCHEMBL12099028

SCHEMBL12099028

Cc1noc(C)c1-c1ccc2c(c1)ncc1nc(C(C)c3ccccc3)n(Cc3ccccc3)c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 13/20 0.49
BRD2 P25440 3/20 0.44
BRD3 Q15059 3/20 0.44
BRDT Q58F21 1/20 0.44
CYP3A4 P08684 3/20 0.44
CYP2C9 P11712 2/20 0.44
CREBBP Q92793 1/20 0.44
USP1 O94782 1/20 0.43
LMNA P02545 3/20 0.42
PIK3CD O00329 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HIF1A Q16665 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12099267 0.89 BRD4 (0.46) BRD4BRD2BRD3BRDTCYP3A4
SCHEMBL12098981 0.86 BRD4 (0.44) BRD4BRD2BRD3BRDTCYP3A4
SCHEMBL12098881 0.80 BRD4 (0.60) BRD4BRD2BRD3BRDTCYP3A4
SCHEMBL12098652 0.78 BRD4 (0.51) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL12099179 0.77 ATM (0.51) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL1905187 0.76 BRD4 (0.58) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL12098956 0.75 PIK3CD (0.48) BRD4BRD2BRD3BRDTCYP3A4
SCHEMBL12098911 0.75 PIK3CD (0.52) BRD4BRD2BRD3BRDTCYP3A4
SCHEMBL12098988 0.73 PIK3CD (0.68) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL12168904 0.73 BRD4 (0.50) BRD4BRD2BRD3CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2496576-B1 IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-12-18 EP disclosed
US-8557984-B2 Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors GLAXOSMITHKLINE LLC (US) 2013-10-15 US disclosed
US-8557984-B2 Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors GLAXOSMITHKLINE LLC (US) 2013-10-15 US disclosed
US-8557984-B2 Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors GLAXOSMITHKLINE LLC (US) 2013-10-15 US disclosed
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors GLAXOSMITHKLINE LLC 2012-09-13 US disclosed
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors GLAXOSMITHKLINE LLC 2012-09-13 US disclosed
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors GLAXOSMITHKLINE LLC 2012-09-13 US disclosed
WO-2011054846-A1 IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors BRD4, BRD3, BRPF3 BRD4 1/4885BRD2 5/4885BRD3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.